UNICANCER clinical trial pipeline

5 trials changed in the last 30 days: 2 stopped, 2 with notable changes, 1 with a minor change only.

1. Stopped

   SAFIR 03 · Detection of Tumor DNA in the Blood of Patients…SAFIR 03 · Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

   Trial terminated

   Also in this update: Final enrollment: 4 participants — 2% of the 162 planned; Primary completion date changed from estimate of Jul 2028 to Mar 30, 2025

   UNICANCER·Phase 2· NCT05625087· Registry history of NCT05625087 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

2. Stopped

   ALTERNATIVE · Telemonitoring Platform "CUREETY TECHCARE" vs…ALTERNATIVE · Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

   Trial terminated

   Also in this update: Final enrollment: 31 participants — 7% of the 472 planned; Primary completion date changed from estimate of Sep 1, 2026 to Dec 1, 2025

   UNICANCER·Not applicable· NCT06505018· Registry history of NCT06505018 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

3. Notable

   METAREM · Immunotherapy Master Trial for Advanced Cancers

   Recruitment opened

   Also in this update: Primary completion pushed from Jun 2028 to Dec 2028

   UNICANCER·Phase 2· NCT07431073· Registry history of NCT07431073 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

4. Notable

   META-1 · Immunotherapy Without Chemotherapy for Advanced Lung…META-1 · Immunotherapy Without Chemotherapy for Advanced Lung Cancer · High PD-L1 Levels

   Recruitment opened

   Also in this update: Primary completion pushed from Jun 2028 to Dec 2028

   UNICANCER·Phase 2· NCT07360743· Registry history of NCT07360743 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.